

Application or Docket Number

Application or Docket Number
10/725720

RCE
10-19-06

(Column 2)

| SMALL ENTITY | |
|--------------|----------|
| RATE | FEE |
| | \$ _____ |
| X \$ _____ = | |
| X \$ _____ = | |
| + \$ _____ = | |
| TOTAL | |

OTHER THAN
SMALL ENTITY

| RATE | FEE |
|------------|--------|
| X \$ _____ | \$ 790 |
| X \$ _____ | — |
| X \$ _____ | — |
| + \$ _____ | — |
| TOTAL | 790 |

TOTAL

SMALL ENTITY

(Column 2)

(Column 3)

| | |
|-------------------------|-------------------|
| RATE | ADDITIONAL FEE |
| X \$ _____ = | |
| X \$ _____ = | |
| + \$ _____ = | |
| TOTAL ADDITIONAL FEE | |

OTHER THAN
SMALL ENTITY

| SMALL ENTRY | |
|-----------------|----------------|
| RATE | ADDITIONAL FEE |
| X \$ _____ = | |
| X \$ _____ = | |
| + \$ _____ = | |
| TOTAL ADD'L FEE | |

(Column 1)

(Column 2)

(Column 3:

| RATE | ADDITIONAL FEE |
|--------------------|----------------|
| X \$ _____ = | |
| X \$ _____ = | |
| + \$ _____ = | |
| TOTAL ADD'L FEE | |

OR

| | |
|-----------------|----------------|
| RATE | ADDITIONAL FEE |
| X \$ _____ = | |
| X \$ _____ = | |
| + \$ _____ = | |
| TOTAL ADD'L FEE | |

(Column 1)

(Column 2)

(Column 3)

| RATE | ADDITIONAL FEE |
|----------------|----------------|
| x \$ _____ = | |
| x \$ _____ = | |
| + \$ _____ = | |
| TOTAL ADD. FEE | |

OR

| RATE | ADDITIONAL FEE |
|-------------------------|----------------|
| X \$ _____ = | |
| X \$ _____ = | |
| + \$ _____ = | |
| TOTAL ADDITIONAL FEE | |

^a WBC: Highest Number of Leukocytes per Cubic Millimeter of Blood. ^b Adapted from [20].

*** If the telephone number is not listed, call the FBI office nearest you.

The Highest Degree Function $f(x) = f(x)$ is independent on the level n of the

α_2 But $p = 1$ and α_2 does not equal p_1 , so $\alpha_2 \neq p_1$. If $p = 0$, and α_2 does not equal p_1 , then α_2 is not equal to p_1 . The path α_2

The exponential random graph approach (ERGM) (Fienberg, 1999) and stochastic block models (SBMs) (Snijders and van de Bunt, 2003) are popular choices to fit the data by the Markov chain Monte Carlo (MCMC) method. The ERGMs are defined by the following log-likelihood function (Fienberg, 1999):

$$l(\theta) = \sum_{i,j \in V} \theta_{ij} x_{ij} + \sum_{i,j \in V} \theta_{ij}^2 x_{ij}^2 + \sum_{i,j \in V} \theta_{ij}^3 x_{ij}^3 + \dots + \sum_{i,j \in V} \theta_{ij}^k x_{ij}^k + \dots$$

where θ_{ij} is the parameter for the edge between nodes i and j , and x_{ij} is the observed value of the edge between nodes i and j . The SBMs are defined by the following log-likelihood function (Snijders and van de Bunt, 2003):

$$l(\theta) = \sum_{i,j \in V} \theta_{ij} x_{ij} + \sum_{i,j \in V} \theta_{ij}^2 x_{ij}^2 + \sum_{i,j \in V} \theta_{ij}^3 x_{ij}^3 + \dots + \sum_{i,j \in V} \theta_{ij}^k x_{ij}^k + \dots$$

where θ_{ij} is the parameter for the edge between nodes i and j , and x_{ij} is the observed value of the edge between nodes i and j .

the fact that the *in vitro* and *in vivo* results are in good agreement, the *in vivo* results are more reliable than the *in vitro* results. The *in vivo* results are more reliable than the *in vitro* results because the *in vivo* results are more reliable than the *in vitro* results.

[illegible]

SEIHO INC. is a company with a Patent No. 1459, Addressed to 2313-1459